Switzerland). The pure peptide was then dissolved in normal saline before infusion. Electrophysiology measurements were performed at three different AII time points: 1) baseline, 2) low-dose infusion (2 ng/kg/min), and 3) high-dose infusion (5 ng/kg/min). These doses were chosen as those that have previously resulted in a significant vasopressor effect (4) . The AII levels were measured at these time points and at 10 min after the AII infusion.
Data are expressed as mean Ϯ SEM. For multiple comparisons between groups, data were analyzed by repeated-measures analysis of variance followed by the Scheffé test for multiple comparisons. Statistical significance was assumed at p Ͻ 0.05.
Twelve patients (8 female/4 male, mean age 37.7 Ϯ 4.2 years) underwent an electrophysiology study. Plasma AII levels were 57.0 Ϯ 14.8 pg/ml at baseline, 85.5 Ϯ 18.7 pg/ml at low dose, 414 Ϯ 153 pg/ml at high dose, and 117.1 Ϯ 51.9 pg/ml at completion (p Ͻ 0.05). A significant hemodynamic response was observed during both low-and high-dose AII infusion (Fig. 1) . Systolic/diastolic blood pressures were 117.0 Ϯ 2.2/76 Ϯ 2.4 mm Hg at baseline; 123.0 Ϯ 2.3/81.6 Ϯ 2.2 mm Hg at low dose (p Ͻ 0.01); 138.0 Ϯ 3.6/91.5 Ϯ 2.9 mm Hg at high dose (p Ͻ 0.01); and 111.6 Ϯ 2.3/73.9 Ϯ 2.3 mm Hg at completion, respectively (Fig. 1) .
Atrial refractoriness did not show a significant acute change in response to AII at any of the sites and cycle lengths tested (Fig. 2) . There was no significant increase in dispersion of ERP in response to AII. Dispersion at 400 ms at baseline was 35.4 Ϯ 9.4 ms, at low-dose AII was 36.1 Ϯ 8.5 ms, and at high-dose AII was 32 Ϯ 6.9 ms. Conduction times as measured in both right and left atria were not significantly altered by AII (Fig. 2) . Conduction delay along the CT as determined by the number and width of double potentials and fractionated signals was not significantly altered by AII. There was no significant change in AF inducibility or duration during either low-or high-dose AII.
This study presents detailed prospective information on the acute atrial electrophysiological effects of AII in humans. No significant direct effects on atrial electrophysiology were observed in response to an infusion of AII sufficient to produce a seven-fold increase in the plasma level of AII and a highly significant hemodynamic response. The AII level achieved was significantly greater than that observed in heart failure (5).
The renin angiotensin system has been implicated previously in acute atrial electrical remodeling. In the rapid atrial pacing model, it has been shown that AII levels increase in the first 24 h and then plateau for the duration of rapid atrial pacing (6). Nakashima et al. (2) demonstrated that dogs treated with either candesartan or captopril showed complete inhibition of electrical remodeling seen in response to 3 h of rapid atrial pacing. They concluded that AII might be implicated in the mechanism of acute remodeling. However, Shinagawa et al (7) observed no effect of enalapril on atrial remodeling in dogs subjected to rapid atrial pacing for seven days.
Several previous animal studies have demonstrated that AII may have direct electrophysiologic effects via modification of ion channel function. However, these effects generally were seen at concentrations beyond physiologic levels.
The renin angiotensin system also has been implicated in chronic atrial remodeling in animals (2, 3, 6, 8) and humans (9) . Seminal work by Li et al. (3) in dogs with heart failure found that enalapril attenuated the effects of heart failure on atrial conduction, fibrosis, and AF promotion. Clinical studies have suggested that AII antagonists or angiotensin-converting enzyme inhibitors may be effective in reducing AF in patients with heart failure or after cardioversion (10,11).
Angiotensin II infusion at doses sufficient to produce significant hemodynamic effects does not have any measurable effect on atrial electrophysiology in humans. It is therefore unlikely to be implicated in the mechanism of acute electrical remodeling. However, these results do not exclude it from having an important role in chronic fibrosis-related remodeling. 
The Prognostic Importance of Body Mass Index After Complicated Myocardial Infarction
To the Editor: Obesity is related to cardiovascular risk factors and is an independent risk factor for coronary artery disease (CAD) and premature death (1,2) . However, the importance of obesity to mortality and morbidity in patients with established CAD is not well defined. The present analysis evaluated the importance of body mass index (BMI) to prognosis after complicated acute myocardial infarction (AMI).
In post-hoc analysis, we examined the impact of baseline BMI on all-cause death, cardiac death (death from AMI, chronic heart failure [CHF], other cardiac causes, and sudden cardiac death), cancer death, and AMI and CHF hospitalization in 5,388 patients with complicated AMI who were included in the OPtimal Trial In Myocardial infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) (3) . Prior to data analysis, patients were categorized into four BMI groups: underweight, Ͻ22.00; normal weight, 22.00 to 24.99; overweight, 25.00 to 29.99; obese, Ն30.00 kg/m 2 . Univariate and multivariate logistic regression analysis and analysis of variance were performed (StatView 5.0.1, SAS Institute, Cary, North Carolina). Multivariate analyses adjusted for 46 variables comprising demographics, patient history, medication, physical examination, and biochemical analyses. Mean study drug dose percent (MSDD%) was calculated as mean percentage of the study drug target dose (captopril/losartan) during each patient's follow-up. We denoted significance to be p Ͻ 0.05.
Baseline BMI ranged from 13.2 to 49.4 kg/m 2 . Table 1 depicts baseline characteristics. Median follow-up was 2.8 years (range 1 to 1,471 days). Table 2 shows the main results of univariate and multivariate analyses. Additionally, BMI categories had similar adjusted risk of cancer death (n ϭ 83), CHF hospitalization (n ϭ 585), and number of CHF hospitalizations (n ϭ 916) and CHF hospitalization days (n ϭ 8,646). One-week mortality was comparable among BMI categories (1.8% to 2.5%). The BMI category was independently (p ϭ 0.018) related to the number of AMIs (n ϭ 975)-adjusted relative frequency compared with normal-weight: underweight, 0.93; overweight, 0.78; obese, 0.82.
In univariate analysis, there was a significant association between BMI category and MSDD%: underweight, 68.55; normal weight, 70.24; overweight, 74.13; obese, 76.91. In univariate analysis, a higher MSDD% was significantly protective of all end points (p Ͻ 0.0001), except cancer death. However, the addition of MSDD% to the multivariate analyses did not attenuate the independent associations shown in Table 2 . 
